# Nuvectis Pharma Inc. (NVCT)

Source: https://www.quantisnow.com/company/NVCT
Generated: 2026-11-13T23:58:03.922Z

- Ticker: NVCT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2022
- SEC CIK: 0001875558
- Website: https://www.nuvectis.com

## About

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

## Latest NVCT news and filings

- 2026-11-04 13:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nuvectis-pharma-inc-6771494)
- 2026-11-04 12:06 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-results-of-operations-6771294)
- 2026-11-04 12:00 UTC [Earnings] [Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights](https://www.quantisnow.com/insight/nuvectis-pharma-reports-third-quarter-2026-financial-results-and-business-6771176)
- 2026-11-02 22:00 UTC [Earnings Date] [Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026](https://www.quantisnow.com/insight/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-6767756)
- 2026-10-26 12:30 UTC [Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas](https://www.quantisnow.com/insight/nuvectis-reports-positive-data-from-nxp200-phase-1b-study-demonstrating-6757149)
- 2026-10-09 12:00 UTC [Conference Announcement] [Nuvectis Pharma to Participate in the Maxim Growth Summit 2026](https://www.quantisnow.com/insight/nuvectis-pharma-to-participate-in-the-maxim-growth-summit-2026-6742384)
- 2026-09-24 12:00 UTC [Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma](https://www.quantisnow.com/insight/nuvectis-announces-nxp200-granted-breakthrough-therapy-designation-in-china-for-6724847)
- 2026-09-03 12:00 UTC [Conference Announcement] [Nuvectis Pharma To Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/nuvectis-pharma-to-participate-in-upcoming-investor-conferences-6704266)
- 2026-08-31 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nuvectis-pharma-inc-6699027)
- 2026-08-24 12:44 UTC [Analyst Coverage Initiated] [Cantor Fitzgerald initiated coverage on Nuvectis Pharma](https://www.quantisnow.com/insight/cantor-fitzgerald-initiated-coverage-on-nuvectis-pharma-6692240)
- 2026-08-21 20:37 UTC [SEC Form S-3] [SEC Form S-3 filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-nuvectis-pharma-inc-6691545)
- 2026-08-21 20:31 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-other-events-financial-6691496)
- 2026-08-05 21:26 UTC [SEC Form 4] [Vice President, Finance Carson Michael J. was granted 30,000 shares, increasing direct ownership by 15% to 230,118 units (SEC Form 4)](https://www.quantisnow.com/insight/vice-president-finance-carson-michael-j-was-granted-30000-shares-6666393)
- 2026-08-04 13:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nuvectis-pharma-inc-6661423)
- 2026-08-04 12:25 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-results-of-operations-6661264)
- 2026-08-04 12:00 UTC [Public Offering] [Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights](https://www.quantisnow.com/insight/nuvectis-pharma-reports-second-quarter-2026-financial-results-and-business-6661149)
- 2026-07-23 13:00 UTC [Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors](https://www.quantisnow.com/insight/correction-title-correction-nuvectis-announces-marketing-approval-of-ciprocopan-nxp100-6646519)
- 2026-07-23 11:30 UTC [Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors](https://www.quantisnow.com/insight/ciprocopan-nxp100-receives-marketing-approval-in-china-for-the-treatment-6646187)
- 2026-07-01 17:41 UTC [Insider Buy] [Large owner Mosseri Marlio Charles bought $916,000 worth of shares (50,000 units at $18.32) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-mosseri-marlio-charles-bought-916000-worth-of-shares-6622477)
- 2026-07-01 17:39 UTC [Insider Buy] [Chairman & CEO Bentsur Ron bought $250,000 worth of shares (12,500 units at $20.00), increasing direct ownership by 0.34% to 3,688,424 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-ceo-bentsur-ron-bought-250000-worth-of-shares-12500-6622473)
- 2026-06-30 20:43 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-entry-into-a-6621084)
- 2026-06-30 20:41 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nuvectis-pharma-inc-6621080)
- 2026-06-30 02:30 UTC [Public Offering] [Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock](https://www.quantisnow.com/insight/nuvectis-pharma-announces-pricing-of-100-million-public-offering-of-6619685)
- 2026-06-29 20:31 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nuvectis-pharma-inc-6619174)
- 2026-06-29 20:07 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-other-events-6618941)
- 2026-06-29 20:01 UTC [Public Offering] [Nuvectis Pharma Announces Proposed Public Offering of Common Stock](https://www.quantisnow.com/insight/nuvectis-pharma-announces-proposed-public-offering-of-common-stock-6618826)
- 2026-06-23 11:00 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-entry-into-a-6611783)
- 2026-06-22 11:30 UTC [Earnings Date] [Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds](https://www.quantisnow.com/insight/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-china-6609984)
- 2026-06-12 20:12 UTC [SEC Form 4] [Director Hoberman Kenneth was granted 35,000 shares, increasing direct ownership by 26% to 168,140 units (SEC Form 4)](https://www.quantisnow.com/insight/director-hoberman-kenneth-was-granted-35000-shares-increasing-direct-ownership-6600330)
- 2026-06-12 20:11 UTC [SEC Form 4] [Director Oliviero James F Iii was granted 35,000 shares, increasing direct ownership by 40% to 122,828 units (SEC Form 4)](https://www.quantisnow.com/insight/director-oliviero-james-f-iii-was-granted-35000-shares-increasing-6600319)
- 2026-06-12 20:11 UTC [SEC Form 4] [Director Sanchez Juan was granted 35,000 shares, increasing direct ownership by 45% to 113,380 units (SEC Form 4)](https://www.quantisnow.com/insight/director-sanchez-juan-was-granted-35000-shares-increasing-direct-ownership-6600316)
- 2026-06-12 20:10 UTC [SEC Form 4] [Director Kaplan Matthew L. was granted 35,000 shares, increasing direct ownership by 28% to 159,760 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kaplan-matthew-l-was-granted-35000-shares-increasing-direct-6600277)
- 2026-06-12 20:05 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-submission-of-matters-6600166)
- 2026-05-14 11:30 UTC [Conference Announcement] [Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ](https://www.quantisnow.com/insight/nuvectis-pharma-inc-to-participate-in-the-hc-wainwright-4th-6552355)
- 2026-05-05 13:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-nuvectis-pharma-inc-6531158)
- 2026-05-05 11:36 UTC [SEC Form 8-K] [Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nuvectis-pharma-inc-filed-sec-form-8-k-results-of-operations-6530815)
- 2026-05-05 11:30 UTC [Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights](https://www.quantisnow.com/insight/nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-6530778)
- 2026-04-27 20:39 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-nuvectis-pharma-inc-6516798)
- 2026-04-27 20:37 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Nuvectis Pharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-nuvectis-pharma-inc-6516783)
- 2026-03-31 12:00 UTC [Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting](https://www.quantisnow.com/insight/nuvectis-pharma-announces-upcoming-presentations-for-nxp900-at-the-2026-6477996)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NVCT
- Earnings history: https://www.quantisnow.com/earnings/NVCT
- Dividend history: https://www.quantisnow.com/dividends/NVCT
- Insider transactions: https://www.quantisnow.com/insiders/NVCT
- Options chain: https://www.quantisnow.com/options/NVCT
- SEC 8-K filings only: https://www.quantisnow.com/company/NVCT/8-k
- RSS and alerts for NVCT: https://www.quantisnow.com/docs/rss-feeds.md